High Risk Investment That Brought Down The U.S. Economy
High Risk Investment That Brought Down The U.S. Economy Returns, With A New Name
When a restaurant fails a health code inspection, sometimes the easiest thing to do is to close up shop, let people forget what happened, then slap a new sign on the door and reopen under a new name. That’s essentially what the world’s biggest banks are doing with a complex, high-risk investment product that helped destroy the global economy less than eight years ago.
Goodbye, “collateralized debt obligations.” Hello, “ bespoke tranche opportunities. ” Banks including Goldman Sachs are marketing that newfangled product, according to Bloomberg, and total sales of “bespoke tranche opportunities” leaped from under $5 billion in 2013 to $20 billion last year.
Like other derivatives, these “BTOs” allow investors to place wagers on the outcome of various loans, bonds, and securities in which they are not directly invested. Hedge funds and other sophisticated financial industry actors use derivatives both as a form of insurance to manage the total risk they are exposed to across their whole investment portfolio, and to gamble on real-world economic events such as mortgage payments, municipal bonds, and the price of physical commodities. The resulting web of complicated contracts can be very difficult to untangle, and can involve impossible-sounding amounts of money. The Financial Crisis Inquiry Commission concluded that derivatives “were at the center of the storm” and “amplified the losses from the collapse of the housing bubble by allowing multiple bets on the same securities.” In 2010, the total on-paper value of every derivative contract worldwide was $1.4 quadrillion, or 23 times the total economic output of the entire planet.
Collateralized debt obligations (CDOs) are a form of derivative that breaks one pool of financial assets — either direct loans or securities that are based on groups of loans — into multiple layers of riskiness. Those layers care called tranches, and investors who buy the least-risky tranche of the derivative will get paid before those who buy the second tranche, and so on. Banks selling traditional CDOs had to create these multiple risk tranches based on a given set of loans or securities, and then hope that someone would buy each of them.
The new “bespoke” version of the idea flips that business dynamic around. An investor tells a bank what specific mixture of derivatives bets it wants to make, and the bank builds a customized product with just one tranche that meets the investor’s needs. Like a bespoke suit, the products are tailored to fit precisely, and only one copy is ever produced. The new products are a symptom of the larger phenomenon of banks taking complex risks in pursuit of higher investment returns, Americans for Financial Reform’s Marcus Stanley said in an email, and BTOs “could be automatically exempt” from some Dodd-Frank rules.
This is not the first time that large banks have tried to reboot the CDO machine since the financial crisis made those products a much-reviled household name. In early 2013, JP Morgan Chase and Morgan Stanley tried and failed to find buyers for a new set of CDOs. The nature of that failure helps illuminate the rationale behind the new version of the product. Finding buyers for the various different layers of risk was “like trying to line up boxcars,” one investor told the Financial Times after the 2013 reboot effort fizzled. Many of the firms that used to buy such products prior to the crisis “no longer exist, and those that survive have very bad memories” of the experience, another analyst said.
Since then, those same old characters seem to have found a way to get back into the business. In addition to Goldman, which narrowly avoided criminal charges after a Senate investigation revealed its shady pre-crisis mortgage dealings, sellers of “bespoke tranche obligations” now include Citigroup and the french banking giant BNP Paribas. BNP’s recent notoriety doesn’t relate to the financial crisis, but rather to the bank’s violation of various U.S. sanctions against Iran, Cuba, and Sudan. And while Citigroup’s past leadership now says financial deregulation was a mistake and that megabanks like Citi should be broken up to protect the economy, its current leadership is chipping away at key Dodd-Frank reforms. Citi was also heavily involved in the “robosigning” scandal that lead to hundreds of thousands or even millions of unjust foreclosures.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Vensure Dives into the World of Background Casting You ever consider just how chaotic a film or TV set can get? One minute things are all glitz and glam, and the next, it's pure mayhem as everything descends into a frenzied dance of coordination chaos. That's the circus of background casting for ya. Vensure's latest venture, Vensure Casting, throws its hat in the ring,...
Continue Reading
Intricacies of Aging: Beyond One-Size-Fits-All So you've hit a point in life where those wrinkles and sagging skin aren't just brushing off with a night's sleep. Enter Dr. Sherif Salama with his treasure trove of options fitting for the fussy nature of skin. The Aging Conundrum: Multifaceted Challenges Aging isn't a one-trick pony. Wrinkles crop up, volume disappears,...
Continue Reading
Leadership Shifts in Gallagher's Upper Echelons What a shake-up at Arthur J. Gallagher & Co.! The power torch is officially passing over in its Benefits & HR Consulting Division. Come January 1, 2027, Tom Doyle is strapping in as the new CEO, taking over from William F. "Bill" Ziebell. Now, don't get too teary-eyed—Ziebell's not vanishing into thin air. Instead, he's...
Continue Reading
Understanding Roof Load Limits You don't have to be in the roofing business to know that Central NY doesn't mess around when winter hits. Michael Majeski, a name trusted in Watertown, NY, is sounding the alarm on how snow and ice can either shake a roof or break it. Talking about roof 'load limits' might sound all fancy, but in plain talk, it's about knowing when your...
Continue Reading
Expanding Expertise in Westchester Today's eye care landscape just got a bit tighter up in Yonkers. SightMD's hauled in a new ace—Dr. Brittany M. Perzia. This isn't your run-of-the-mill hire. The good doctor packs a solid punch in Cornea & External Disease, aiming her skills at the folks around Westchester. It's not just about the numbers with her, though. Her resume's...
Continue Reading
Stablecoin Strategy Meets Institutional Investment Here's a fresh one from the digital asset universe. We're talking about Qapture Investments' bold move to launch an institutional-grade stablecoin yield strategy. This ain't your average kitchen table crypto chat—it's the Qapture Safe Haven Vault (QHVN-USD), tailored for those looking to get a better return on their...
Continue Reading
Independents Take Center Stage on Election Night 2026 Over the years, I've seen plenty of unexpected movements in the market, but this is something unique—a seismic shift, not in finance, but in the political landscape. Election Night 2026 is shaping up to be a real game-changer, as independents step away from the sidelines and demand attention. It's a first-of-its-kind...
Continue Reading
Shifting the GERD Treatment Paradigm While everyone's talking about breakthrough technologies like AI and blockchain in medicine, MemorialCare seems to have quietly flipped the script on treating gastroesophageal reflux disease (GERD). They're sidestepping conventional maneuvers by embracing two procedures known as transoral incisionless fundoplication (TIF) and its...
Continue Reading
Revolutionizing In-Vehicle AI with Big Names Boy, driving ain't what it used to be, and PATEO's latest adventure has a lot to do about it. They've hooked up with some major players like NVIDIA and ByteDance to really shake up the in-car AI scene. We're not just talking bells and whistles, but a true reinvention trying to blend AI straight into our daily grind on the road....
Continue Reading
Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...
Continue Reading
Top 5 Most Recently Viewed Articles
Argentina faced a staggering spike in poverty in the first half of 2024, with rates soaring to an eye-watering 52.9%, according to the INDEC agency. Just a year prior, this figure stood at 40.1%, illustrating the dire economic conditions that have gripped the nation and left many families struggling for survival. Poverty Surge: A Year of Distress The last reported figure...
Continue Reading
Global Atomic Corporation Plans to Raise C$30 Million Global Atomic Corporation is announcing a significant move aimed at enhancing its operations and project development. The company is set to initiate a non-brokered private placement to capitalize on the market's interest, targeting gross proceeds of up to C$30 million. This funding will be achieved through the sale of...
Continue Reading
Counting Sheep: More Minutes or Just More Trouble? As Americans prepare for the clocks to fall back, many dream of an extra hour of sleep. But according to Withings, the reality is far less restful. Despite the clock change promising more shut-eye, folks average just 11 minutes extra sleep, only to watch that dissipate in the days following. Somehow, we lose more than we...
Continue Reading
RPM International's Earnings Surprise In the recent trading session, RPM International Inc witnessed a remarkable surge in its stock price following the announcement of its quarterly earnings, which significantly exceeded analysts' expectations. Financial Performance Overview The company reported an earnings per share (EPS) of $1.72, surpassing the anticipated $1.59 per...
Continue Reading
SomaCell™ Launch Event Shines Ahead of Fashion Week Discover a new era in non-surgical facial regeneration. IT Intelligent Treatment, a leading clinic in medical aesthetics, is excited to announce the launch of its innovative SomaCell™ treatment. This event will occur in an engaging environment just before the vibrant buzz of New York Fashion Week. The SomaCell™...
Continue Reading